OBJECTIVES This report describes the immediate, 1-, and 5-year follow-up results of the U.S. Food and Drug Administration Continued Access clinical trial of the GORE HELEX Septal Occluder (W. L. Gore & Associates, Inc., Flagstaff, Arizona) for closure of secundum atrial septal defect. to allow continued enrollment in a trial of the investigational device during review of data from the Pivotal Trial. Devices with hydrophilic coating on the expanded polytetrafluoroethylene to improve echocardiographic visualization were first used in this trial.
modified with the addition of a hydrophilic coating on the Gore-Tex to improve echocardiographic visualization for the Continued Access study.
The HELEX is a circular double-disk device composed of a single flexible nitinol wire frame helically shaped and draped with a thin membrane of expanded polytetrafluoroethylene (ePTFE). The device is repositionable during its deployment and is retrievable even after initial release from the delivery system by a retrieval chord or string that tethers the occluder to the delivery system until final release.
METHODS
The Continued Access trial was begun in May 2003 at 13 clinical centers ( Table 1) .
Each center obtained approval from its institu- Pre-procedure evaluation included history and physical, electrocardiogram, and transthoracic echocardiogram. The same evaluations were performed pre-hospital discharge and again at 1, 6, 12, 36, 48, and 60 months post-implantation. Fluoroscopy of the device was performed at 6, 12, and 60 months to assess for wire frame fracture. OUTCOME MEASURES. The primary endpoint of the Continued Access study was clinical success, a composite variable evaluating safety and efficacy, at Patient, ASD, and HELEX device characteristics are provided in Table 2 . Implantation and follow-up compliance for these 137 patients are shown in Wire frame fracture data are shown in Table 5 . Residual shunting data are shown in Table 6 . The echocardiographic core laboratory was instructed to classify studies in which all ideal views were not obtainable (could not definitely rule out a leak) into the appropriate clinically significant or insignificant leak category. This policy was used to ensure that the Values shown are number (%). Percentages use patients available for interval follow-up as the denominator (unless otherwise noted). Follow-up windows are as follows: predischarge, days 0 to 2; 1 month, days 15 to 46; 6 months, days 151 to 244; 12 months, days 245 to 548; 36 months, days 913 to 1,276; 60 months, days 1,642 to 2,006. *Number of patients with a successful HELEX device placement. †Patients available for interval follow-up equal the total number of patients minus patients who discontinued before the interval and patients not reached at start of interval. ‡Fluoroscopy required at 6, 12, and 60 months. §Patients currently in study interval, but no visit reported at time of analysis. kPatients available for follow-up visit at start of interval, but discontinued in window and before visit. These patients are included in patients who discontinued before interval in next time interval. ¶Patients completed study interval window with no visit reported. Table 6 ). Clinical success endpoints at 12, 36, and 60 months are shown in Table 9 . additional ASDs that required treatment that would be best addressed surgically (protocol did not allow additional devices). None of these 4 major adverse events resulted in clinical manifestations (all patients were asymptomatic before the decision to intervene).
STUDY LIMITATIONS. First, this study was not designed for comparison with other devices or techniques, nor was it designed as a randomized 
